Scientists Investigating Alzheimer’s Drug Faulted in Leaked Report
A professor at the City College of New York engaged [...]
New Study Finds Alzheimer’s Drug Donanemab Can Modestly Slow Memory Decline
A trial of donanemab, an experimental drug, found it modestly [...]
Leqembi: lo que hay que saber sobre el fármaco contra el alzhéimer
Medicare cubrirá gran parte del costo para los pacientes en [...]
What to Know About Leqembi, the Alzheimer’s Drug Approved by the FDA
Medicare will cover much of the cost for patients in [...]
FDA Makes Alzheimer’s Drug Leqembi Widely Accessible
The F.D.A. gave full approval to the drug, but added [...]
Eli Lilly Trial Finds Alzheimer’s Drug Can Slow Progress of Disease
Donanemab is not a cure and comes with significant side [...]
FDA Approves, Leqembi, New Treatment for Early Alzheimer’s
The drug, Leqembi, may modestly slow cognitive decline in early [...]
Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen
The report said the F.D.A.’s approval process for Aduhelm was [...]
Alzheimer’s APOE4 Genetic Risk Targeted in Promising Trial
Preliminary results offer hope that gene therapy can protect people [...]
Alzheimer’s Drug May Benefit Some Patients, New Data Shows
The drug, lecanemab, made by Eisai and Biogen, also carried [...]